| Prev Close | 254.16 |
| Day Low/High | 251.71 / 254.99 |
| 52 Wk Low/High | 184.50 / 256.80 |
| Avg Volume | 2.20M |
| Exchange | NYSE |
| Shares Outstanding | 335.87M |
| Market Cap | 85.36B |
| EPS | 38.20 |
| P/E Ratio | N/A |
| Div & Yield | 2.80 (1.10%) |
Latest News
No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)
Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.
Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round
Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.
7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods
Here are the activist investor's next potential targets.
Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)
Jim Cramer says these market rotations are crushing good stocks that don't deserve it.
Allergan Achieves #90 Analyst Rank, Surpassing Danaher
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Allergan PLC has taken over the #90 spot from Danaher Corp , according to ETF Channel. Below is a chart of Allergan PLC versus Danaher Corp plotting their respective rank within the S&P 500 over time (AGN plotted in blue; DHR plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
Weekly Roundup
The market surged this week as positive earnings and a mellower tone from Janet Yellen cheered bulls.
Alder BioPharmaceuticals: Cramer's Top Takeaways
Jim Cramer warns that development stage biotechs are for speculation only.
'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)
Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
Portfolio Update: Western Digital, Allergan and Cisco
We are actively looking at CSCO to make a move.
As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals
The Trump administration's creep towards scrapping certain tax regulations could revive inversion deals that have allowed U.S. companies to avoid billions of dollars in taxes.
Treasury Proposal Could Revive Inversions, Reinstate Other Tax Savings Tactics
The Treasury Department is targeting a handful of Obama-era tax rules for reform, including one that could resurrect corporate inversions.
See America Furthers The Fight Against Preventable Blindness With #EyePic Campaign
Allergan partners with Milo Ventimiglia, Victor Cruz, and Alexandra Daddario to promote vision health and raise money for the American Foundation for the Blind
Weekly Roundup
Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.
Allergan, Celgene Offer Solid Biotech Value
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
AGN NOTICE: Rosen Law Firm Reminds Allergan, Inc. Investors Of Important Deadline In Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan, Inc.
Allergan, Celgene Offer Solid Biotech Value
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
Allergan, Celgene Offer Solid Biotech Value
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Allergan, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of investors that sold the call options, purchased the put options and/or sold equity forward contracts of...
